S2B Syn2bio S.A.

13.43USD53.98 PLN · GPW-2.56%Mkt Cap: 120.35M USDP/E: —

Syn2bio S.A. operates as a biotechnology company. It engages in the development and commercialization of SYN2 cardiotracer, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery…

Key Statistics

Company
Market Cap120.35M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-5.89M USD
Revenue/Share—
Last Price13.43 USD
Fiscal Year End—
MR Quarter—
Employees—
CountryPL
SectorHealthcare
IndustryBiotechnology
ISINPLSNBIO00013
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-0.71 USD
EPS (Forward)—
52W Range
6.52039% of range24.04
52W High24.04 USD
52W Low6.520 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-141.89%
ROA-90.29%
ROIC-233.85%
ROCE-166.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.03M USD
CapEx (TTM)218.54K USD
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity0.04
Current Ratio—
Quick Ratio—
Book Value/Sh—
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.715 USD
Upside (mean)-42.6%
Target Range7.715 USD – 7.715 USD
# Analysts1
Ownership
Shares Out.8.73M
Float—
Insiders39.79%
Institutions8.54%
Technical
SMA 5016.04 (-16.3%)
SMA 20013.64 (-1.5%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)13.49K
Avg Vol (10d)17.63K
Technical Indicators
RSI (14)34.8
MACD-1.4628
MACD Signal-0.9496
MACD Hist.-0.5132
BB Upper16.34 USD
BB Middle15.20 USD
BB Lower14.05 USD
BB Width15.08%
ATR (14)0.8030 USD
Vol Ratio (20d)1.24x

About Syn2bio (WSE: S2B)

›

Syn2bio (WSE: S2B) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 53.98 PLN on 20 November 2026. Its 52-week range is 26.20 PLN to 96.60 PLN: the price is 44.1% below the high and 106.0% above the low.

Its market capitalisation is 483.59M PLN.

Syn2bio reports return on equity of -141.9% and an operating margin of 0.0%.

Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 31.00 PLN is 42.6% below the current price.